← Eichor
Condition: Neurotoxicity Syndromes Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Neurotoxicity Syndromes

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies W
Phase N/A · 3 location(s) · National Cancer Institute (NCI) · NCT05237986Temporal Characterization of Extracellular Vesicles During Cellular Therapy Using CAR-T Cells and During the Occurrence
Phase 4 · 1 location(s) · Centre Hospitalier Universitaire de Saint Etienne · NCT06706102Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy
NA · 2 location(s) · Instituto de Investigacion Sanitaria INCLIVA · NCT07173166"The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients"
Phase 2 · 1 location(s) · Ain Shams University · NCT06679387Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations
Phase 4 · 1 location(s) · University of British Columbia · NCT05089604Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07169487ADC-induced Neurotoxicity Treated With Duloxetine
Phase 2 · 1 location(s) · Fudan University · NCT06551051Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Ce
Phase 2 · 1 location(s) · OHSU Knight Cancer Institute · NCT06895473A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
Phase N/A · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT07249528Injection of Botulinum Toxin for Thumb Carpometacarpal Arthritis
Phase 3 · 1 location(s) · Rhode Island Hospital · NCT05990881A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT06144151Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Phase 2 · 17 location(s) · SCRI Development Innovations, LLC · NCT05972135Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leuke
Phase 2 · 1 location(s) · Northside Hospital, Inc. · NCT05519579International CIPN Assessment and Validation Study
Phase N/A · 30 location(s) · University of Milano Bicocca · NCT04633655Table-Top Water Pitcher to Reduce Arsenic Exposure Among Well Users in New Hampshire
NA · 1 location(s) · Trustees of Dartmouth College · NCT07103356Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy
NA · 2 location(s) · Ka-Wai Ho · NCT07095998Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels
NA · 1 location(s) · University Hospital, Clermont-Ferrand · NCT06649474EGCG for the Prevention and Treatment of TIPN
Phase 1/Phase 2 · 1 location(s) · Han Xi Zhao · NCT06524609Neuroimaging and Biomarkers of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy
Phase N/A · 1 location(s) · University of California, San Diego · NCT07075523Chemotherapy Induced Peripheral Neurotoxicity (CIPN): Why Should we Care
Phase N/A · 1 location(s) · University of Milano Bicocca · NCT04986891Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionat
Phase N/A · 1 location(s) · Chang Gung Memorial Hospital · NCT04006561Longitudinal Cohort Study of Immune-Related Adverse Events in Solid Tumor Patients Treated With Immune Checkpoint Inhibi
Phase N/A · 6 location(s) · Shantou University Medical College · NCT07357636Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Phase 2 · 6 location(s) · Ontario Clinical Oncology Group (OCOG) · NCT06421675Atamparib in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Nerviano Medical Sciences (Shanghai) Ltd. · NCT07374419Extracellular Vesicles and Chemotherapy-Induced Peripheral Neuropathy
NA · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07558447Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
NA · 1 location(s) · University of Utah · NCT07390071A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07106671Biomarker and Imaging Package Study in Immune Effector Cell-Associated Neurotoxicity Syndrome
Phase N/A · 1 location(s) · zhang shoulong · NCT05643092rTMS as an Intervention for Levodopa-induced Dyskinesia
NA · 1 location(s) · Danish Research Centre for Magnetic Resonance · NCT06570824
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.